{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:17:31Z","timestamp":1790702251399,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s13555-014-0053-2","type":"journal-article","created":{"date-parts":[[2014,5,27]],"date-time":"2014-05-27T10:56:35Z","timestamp":1401188195000},"page":"115-124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Psoriasis Causes Significant Economic Burden to Patients"],"prefix":"10.1007","volume":"4","author":[{"given":"A.","family":"Mustonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mattila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Leino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Koulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Tuominen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,28]]},"reference":[{"issue":"5","key":"53_CR1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.clindermatol.2007.10.024","volume":"26","author":"MA Radtke","year":"2008","unstructured":"Radtke MA, Augustin M. Economic considerations in psoriasis management. Clin Dermatol. 2008;26(5):424\u201331.","journal-title":"Clin Dermatol"},{"issue":"1","key":"53_CR2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1468-3083.2001.00192.x","volume":"15","author":"SP Raychaudhuri","year":"2001","unstructured":"Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001;15(1):16\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"53_CR3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2005.03.046","volume":"53","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"53_CR4","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/rheumatology\/35.12.1289","volume":"35","author":"O Kaipiainen-Seppanen","year":"1996","unstructured":"Kaipiainen-Seppanen O. Incidence of psoriatic arthritis in Finland. Br J Rheumatol. 1996;35(12):1289\u201391.","journal-title":"Br J Rheumatol"},{"issue":"2","key":"53_CR5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1684\/ejd.2011.1623","volume":"22","author":"J Lambert","year":"2012","unstructured":"Lambert J, Dowlatshahi EA, de la Brassinne M, Nijsten T. A descriptive study of psoriasis characteristics, severity and impact among 3,269 patients: results of a Belgian cross sectional study (BELPSO). Eur J Dermatol. 2012;22(2):231\u20137.","journal-title":"Eur J Dermatol"},{"issue":"9","key":"53_CR6","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archderm.143.9.1113","volume":"143","author":"T Nijsten","year":"2007","unstructured":"Nijsten T, Looman CW, Stern RS. Clinical severity of psoriasis in last 20\u00a0years of PUVA study. Arch Dermatol. 2007;143(9):1113\u201321.","journal-title":"Arch Dermatol"},{"issue":"11","key":"53_CR7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2165\/11591580-000000000-00000","volume":"30","author":"G Raho","year":"2012","unstructured":"Raho G, Koleva DM, Garattini L, Naldi L. The burden of moderate to severe psoriasis: an overview. Pharmacoeconomics. 2012;30(11):1005\u201313.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"53_CR8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000090654","volume":"212","author":"S Sohn","year":"2006","unstructured":"Sohn S, Schoeffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology. 2006;212(2):137\u201344.","journal-title":"Dermatology"},{"issue":"5\u20136","key":"53_CR9","first-page":"85","volume":"140","author":"AA Navarini","year":"2010","unstructured":"Navarini AA, Laffitte E, Conrad C, et al. Estimation of cost-of-illness in patients with psoriasis in Switzerland. Swiss Med Wkly. 2010;140(5\u20136):85\u201391.","journal-title":"Swiss Med Wkly"},{"issue":"7","key":"53_CR10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1610-0387.2005.05729.x","volume":"3","author":"K Berger","year":"2005","unstructured":"Berger K, Ehlken B, Kugland B, Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges. 2005;3(7):511\u20138.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"9","key":"53_CR11","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1468-3083.2010.03600.x","volume":"24","author":"N Meyer","year":"2010","unstructured":"Meyer N, Paul C, Feneron D, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010;24(9):1075\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"53_CR12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1610-0387.2007.06240.x","volume":"5","author":"O Schoffski","year":"2007","unstructured":"Schoffski O, Augustin M, Prinz J, et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges. 2007;5(3):209\u201318.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"53_CR13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1684\/ejd.2011.1635","volume":"22","author":"O Ghatnekar","year":"2012","unstructured":"Ghatnekar O, Ljungberg A, Wirestrand LE, Svensson A. Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden\u2014a cross-sectional study. Eur J Dermatol. 2012;22(2):238\u201345.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"53_CR14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1684\/ejd.2013.1969","volume":"23","author":"K Mattila","year":"2013","unstructured":"Mattila K, Leino M, Mustonen A, Koulu L, Tuominen R. Influence of psoriasis on work. Eur J Dermatol. 2013;23(2):208\u201311.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"53_CR15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s13555-013-0030-1","volume":"3","author":"J Ruano","year":"2013","unstructured":"Ruano J, Isla-Tejera B, Jimenez-Puya R, Rodriguez-Martin A, Cardenas M, Gomez F, et al. Long-term cost-effectiveness analysis of etanercept and adalimumab for plaque psoriasis not associated with arthritis. Dermatol Ther (Heidelb). 2013;3(2):131\u201342.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"53_CR16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/14656566.7.2.157","volume":"7","author":"DW Miller","year":"2006","unstructured":"Miller DW, Feldman SR. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother. 2006;7(2):157\u201367.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"53_CR17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/09546630903440080","volume":"22","author":"BA Yentzer","year":"2011","unstructured":"Yentzer BA, Feldman SR. Trends in home phototherapy adoption in the US: monetary disincentives are only the tip of the iceberg. J Dermatol Treat. 2011;22(1):27\u201330.","journal-title":"J Dermatol Treat"},{"key":"53_CR18","first-page":"200","volume":"17","author":"CS Hankin","year":"2005","unstructured":"Hankin CS, Feldman SR, Szczotka A, et al. A cost comparison of treatments of moderate to severe psoriasis. Drug Benefit Trends. 2005;17:200\u201314.","journal-title":"Drug Benefit Trends"},{"issue":"1","key":"53_CR19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/09546630500504754","volume":"17","author":"DJ Pearce","year":"2006","unstructured":"Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatol Treat. 2006;17(1):29\u201337.","journal-title":"J Dermatol Treat"},{"issue":"9","key":"53_CR20","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1517\/14656566.4.9.1525","volume":"4","author":"SR Feldman","year":"2003","unstructured":"Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother. 2003;4(9):1525\u201333.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"53_CR21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/09546630903551258","volume":"22","author":"AH Anis","year":"2011","unstructured":"Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatol Treat. 2011;22(2):65\u201374.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"53_CR22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000051583","volume":"202","author":"MA Rie de","year":"2001","unstructured":"de Rie MA, de Hoop D, Jonsson L, Bakkers EJ, Sorensen M. Pharmacoeconomic evaluation of calcipotriol (Daivonex\/Dovonex) and UVB phototherapy in the treatment of psoriasis: a Markov model for The Netherlands. Dermatology. 2001;202(1):38\u201343.","journal-title":"Dermatology"},{"issue":"1","key":"53_CR23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/00015550310015833","volume":"84","author":"M Uttjek","year":"2004","unstructured":"Uttjek M, Dufaker M, Nygren L, Stenberg B. Determinants of quality of life in a psoriasis population in northern Sweden. Acta Derm Venereol. 2004;84(1):37\u201343.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"53_CR24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2008.03.045","volume":"59","author":"A Storm","year":"2008","unstructured":"Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59(1):27\u201333.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"53_CR25","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1468-3083.2006.01659.x","volume":"20","author":"JM Carrascosa","year":"2006","unstructured":"Carrascosa JM, Pujol R, Dauden E, et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol. 2006;20(7):840\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"53_CR26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/09546630510025941","volume":"16","author":"SR Feldman","year":"2005","unstructured":"Feldman SR, Evans C, Russell MW. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatol Treat. 2005;16(1):37\u201342.","journal-title":"J Dermatol Treat"},{"issue":"2","key":"53_CR27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13555-013-0040-z","volume":"3","author":"A Mustonen","year":"2013","unstructured":"Mustonen A, Mattila K, Leino M, Koulu L, Tuominen R. The costs of psoriasis medications. Dermatol Ther (Heidelb). 2013;3(2):169\u201377.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"Suppl 3","key":"53_CR28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-3083.2005.01329.x","volume":"19","author":"S Fouere","year":"2005","unstructured":"Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005;19(Suppl 3):2\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"53_CR29","first-page":"957","volume":"11","author":"JW Wong","year":"2012","unstructured":"Wong JW, Davis SA, Feldman SR, Koo JY. Trends in older adult psoriasis outpatient health care practices in the United States. J Drugs Dermatol. 2012;11(8):957\u201362.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"53_CR30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF03261868","volume":"10","author":"R Vender","year":"2012","unstructured":"Vender R, Lynde C, Ho V, Chau D, Poulin-Costello M. Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting. Appl Health Econ Health Policy. 2012;10(5):343\u201353.","journal-title":"Appl Health Econ Health Policy"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-014-0053-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T01:19:53Z","timestamp":1716772793000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-014-0053-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,28]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["53"],"URL":"https:\/\/doi.org\/10.1007\/s13555-014-0053-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,28]]}}}